Aster DM Quality Care Limited is the merged hospital platform formed when Aster DM Healthcare and Quality Care India combined effective July 1, 2026, creating one of India's largest private hospital operators with roughly 39 hospitals, more than 10,800 beds across 28 cities and 9 states, and nearly 8 million patients treated over the last twelve months. The money is made inside the hospitals through high-acuity super-specialty care in oncology, cardiology, neurosciences and transplants, supplemented by diagnostics and pharmacy adjacencies. The internal unit structure reveals where quality sits: mature units generate 73% of revenue at 30% EBITDA margins, focus units 15% of revenue in the teens, and emerging units are scaling fast at 63% revenue growth with margins that doubled to 12.4%. Combined proforma Q1FY27 revenue was INR 2,597 crores, up 20%, with operating EBITDA up 30% to INR 576 crores at a 22.2% margin, and return on capital employed improved about 190 basis points to 22.6%. For Indian hospitals, sustained unit-level margins above 25% are exceptional, and the fact that every mature asset clears that bar signals genuine operating quality rather than a commodity bed-rental business.
The economics persist because of assets that take years to replicate. The network holds JCI-accredited flagship units, claims top or top-two position in India on cardiology volume, runs one of Asia's top five DBS programs, and performed India's first robotic hepatic artery infusion therapy. Clinical talent is the real moat: departed clinician teams have rejoined, 100-plus clinicians were onboarded in FY26 generating recurring revenue, and management cites a strong bias among doctors toward the merged platform. The Tier-2 execution playbook is proven and repeatable: Nagercoil turned profitable within four months of opening and now runs near INR 180 crores of annualized revenue at close to 30% EBITDA, while Kasaragod reached EBITDA breakeven just nine months after commissioning. Brownfield additions are demonstrably accretive, as MIMS Kannur's margin expanded 400 basis points after adding 100 beds. This is not a commoditized market; micro-market density, brand pull and clinician loyalty create switching dynamics that competitors cannot quickly copy.
The inflection is the merger itself plus a concrete capacity pipeline. Synergies of INR 150 to 200 crores, equal to 10-15% of FY24 proforma EBITDA, begin flowing in FY27 and annualize in FY28. Management has committed to adding over 4,170 beds over three to four years to exceed 15,000 total, with 53% brownfield-led for faster gestation. Dated milestones anchor the next 18-24 months: the Raipur cancer center opened mid-August 2026, the Trivandrum hospital targets around January 2027, Hyderabad operationalizes around April 2027, Sarjapur Phase I arrives in H2 FY28, and Kottayam, Nagercoil, Banjara Hills, Nampally and Shifa additions all land by 2028. By early-to-mid 2028 the platform should be running roughly 12,000 beds, sustaining low-to-mid-teens revenue growth with EBITDA growing several points faster, CONGO-T mix moving from the current mid-to-high 50s toward the 60-65% target, medical value travel compounding above 50% annually toward double-digit revenue share, and blended margins tracking from 22.2% toward the guided 24-25% expected between 2028 and 2029.
Management's walk matches its talk. Guidance called for mid-teens revenue growth and roughly 20% standalone margins in FY26, and delivery came in at 10% reported but 21.7% ex-Kasargod margins with normalized PAT up 26% to INR 451 crores. Kerala's 25% cluster margin promise was met at 25.4%, the Whitefield 159-bed block and Kasargod commissioned within their guided windows, and Aster Labs swung from negative 7.6% EBITDA margin in FY24 to positive 12.8% in FY26. The merger cleared 96.7% shareholder approval and CCI before NCLT sanction, exactly as sequenced across four calls. Capital allocation is conservative: combined net debt stands at INR 1,162 crores against Aster's INR 511 crore net cash position, expansion is funded without equity dilution, and minority interest is guided at a blended 10-15% of profits.
The earnings path is quantified: reaching 24-25% EBITDA margins requires 5-6% volume growth plus 7-8% ARPP growth, layered with synergies annualizing in FY28 and emerging-unit margins maturing toward the 25% unit-level framework. The Q1FY27 tension between a 22% PAT drag from INR 114 crores of one-time merger costs and 39% growth in normalized PAT resolves cleanly as transactional, not structural. The falsifier is synergy realization, which has not yet shown up in reported numbers since it only began this financial year, compounded by greenfield timeline risk at Trivandrum and Hyderabad and prior doctor attrition episodes in Bengaluru micro-markets. Management gives no interim quarterly guidance, so the single most important watchpoint is whether synergy savings and new-hospital ramps appear in the FY28 run-rate; if margins stall below 23% through FY28 with Trivandrum slipping, the 24-25% target fails.
companyname: Aster DM Quality Care Limited (formerly Aster DM Healthcare Limited) ticker: ASTERDM sector: Healthcare – Hospital Services Aster DM Quality Care Limited is an Indian hospital network formed by the merger of Aster DM Healthcare and Blackstone-backed Quality Care India Ltd (QCIL), effective July 1, 2026. The combined entity operates roughly 39 hospitals with about 45,000 healthcare professionals, including over 7,000 doctors, across 28 cities and 9 states in India (Q1 FY27 concall, ...
Read the full report →capex, margin expansion, acquisition inorganic
Over the next four years, Aster DM Healthcare plans to add ~2,500 beds at the cost of INR 2700 crores.
Guidance no_dataconsistent
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Aster DM Healthcare Limited and 4,900+ companies.
5-day free pass. No card required.